Current antiretroviral therapy: An overview Article Conference Paper uri icon


MeSH Major

  • Anti-HIV Agents
  • HIV Infections
  • HIV Protease Inhibitors
  • Patient Selection


  • Advances in the understanding of human immunodeficiency virus (HIV) pathogenesis, clinical assessment with viral load testing and the availability of potent combination antiretroviral therapy regimens have led to significant changes in options for HIV-infected patients. From the first approved antiretroviral agent, zidovudine (AZT), through two-drug nucleoside analogue regimens, to the current three-drug combination regimens with protease inhibitors, both the benefits of therapy and the complexities of therapy continue to increase. With the clinical benefits come associated lifestyle constraints and, thus, the impact and assessment of potent antiretroviral therapy on patient quality of life (QoL) becomes increasingly complicated.

publication date

  • October 20, 1997



  • Conference Paper


Digital Object Identifier (DOI)

  • 10.1023/A:1018447829842

PubMed ID

  • 9330547

Additional Document Info

start page

  • 471

end page

  • 4


  • 6


  • 6